G2TT
来源类型Dissertations
规范类型其他
DOIhttps://doi.org/10.7249/RGSD422
来源IDRGSD-422
Three Essays in Health Economics: Towards Alternative Payment Models for High-Value, High-Cost Medical Treatments
Jakub P. Hlavka
发表日期2018
出版年2018
页码55
语种英语
摘要

The emergence of high-cost treatments has accelerated the pace of discussions about alternative payment models that would simultaneously enable rapid patient access while ensuring sustainable health care spending. However, limited empirical research exists on the magnitude of the problem and the expected performance of such payment models.

The first paper presents a pipeline analysis of regenerative treatments in clinical trials. It finds that there are nearly 50 late-stage clinical trials that could produce regenerative drugs with potentially high prices. Alzheimer's disease poses the largest budget impact risk for U.S. payers, with new spending likely to exceed $50 billion annually. Spending on several other regenerative treatments, including treatments for traumatic brain injury, X-linked retinoschisis and congestive heart failure, could each exceed $5 billion annually.

The second paper studies a novel payment model linking a drug's performance to pre-negotiated price levels. Drawing on the Future Elderly Model (FEM), it estimates the clinical benefits of PCSK9 inhibitors under three different efficacy scenarios. It shows that an adaptive pricing approach has the potential to lower the cost per event avoided under a low-efficacy scenario, thus avoiding unnecessary spending, should the drug not meet clinical trial efficacy in the real world.

The third paper studies deferred payment in a gene therapy for congestive heart failure. It draws on a simulation of more than 91,000 Medicare fee-for-service beneficiaries over a period of 3 years and finds that deferred payment results in a 26.1% reduction of cardiovascular admissions and a 23.3% reduction of deaths over a three-year period, both relative to status quo payment and assuming a fixed budget constraint. Financial gains to payers and manufacturers are relatively minimal, with savings on avoided admissions amounting to just 0.3% of total spending, primarily due to the small share of expected cost savings on the total cost of therapy.

The dissertation finds that large budget pressures resulting from regenerative treatments will be driven by several specific indications, and tests how two different payment models could help address the uncertainty about clinical benefits and the high upfront cost of some emerging therapies.

目录

Table of Contents

  • Paper I

    Budget Impact of Cures

  • Paper II

    Three-Part Pricing for Drugs of Uncertain Efficacy

  • Paper III

    The Benefits of Deferred Payment in Congestive Heart Failure Gene Therapy

主题Health Care Payment Approaches ; Health Economics
URLhttps://www.rand.org/pubs/rgs_dissertations/RGSD422.html
来源智库RAND Corporation (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/112015
推荐引用方式
GB/T 7714
Jakub P. Hlavka. Three Essays in Health Economics: Towards Alternative Payment Models for High-Value, High-Cost Medical Treatments. 2018.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
x1545054548912.jpg(4KB)智库出版物 限制开放CC BY-NC-SA浏览
RAND_RGSD422.pdf(531KB)智库出版物 限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jakub P. Hlavka]的文章
百度学术
百度学术中相似的文章
[Jakub P. Hlavka]的文章
必应学术
必应学术中相似的文章
[Jakub P. Hlavka]的文章
相关权益政策
暂无数据
收藏/分享
文件名: x1545054548912.jpg
格式: JPEG
文件名: RAND_RGSD422.pdf
格式: Adobe PDF

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。